MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative

    G. Mills, R. Chapman, S. Collins, R. Ellis-Doyle, C. Gonzalez-Robles, M. Zeissler, O. Bandmann, R. Barker, J. Carpenter, J. Chataway, J. Duffen, S. Gandhi, K. Mcfarthing, S. Mullin, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To design an optimal multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in Parkinson’s disease (PD). Background: The current clinical trials process cannot…
  • 2023 International Congress

    Age at Onset and Therapeutic Efficacy of Primidone in Essential Tremor Patients

    F. Jamal, G. Jackson, A. Sarwar, P. Mandava (Houston, USA)

    Objective: To study the therapeutic response of primidone in different age groups of Essential Tremor (ET) patients, based on age at onset. Background: Essential Tremor…
  • 2023 International Congress

    Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerobridase (GCase)

    L. Magalhães, M. Fonseca, G. Castilla-Fernández, R. Costa, D. Simon, J. Holenz, N. Mendonça (Coronado, Portugal)

    Objective: To assess the efficacy of BIA 28-6156 in delaying clinically meaningful motor progression in PD patients who have a PD-risk associated variant in the…
  • 2023 International Congress

    Speech difficulties and dopaminergic neurodegeneration in Parkinson’s Disease

    S. Polychronis, B. Ribba, G. Nasios, E. Dardiotis, G. Pagano (Ioannina, Greece)

    Objective: To evaluate the association between speech difficulties and neurodegeneration of the putaminal dopaminergic system in people with early-stage treated with symptomatic therapy and advanced-stage…
  • 2023 International Congress

    Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease

    K. Peikert, A. Spranger, E. Fischer, H. Glaß, B. Falkenburger, G. Miltenberger-Miltenyi, D. Tyteca, C. Klose, D. Grossmann, A. Hermann (Rostock, Germany)

    Objective: To study the overall lipid composition and distribution in red blood cells (RBCs) and neurons derived from VPS13A disease patients, a neurodegenerative disorder associated…
  • 2023 International Congress

    Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers

    C. Marras, D. Weintraub, J. Beck, A. Naito, Z. Meyer, N. Dahodwala, T. Davis, K. Mills, J. Miyasaki, S. Mantri, M. Neault, A. Brown, A. Allen, E. Nelson, H. Liu (Toronto, Canada)

    Objective: Implement depression screening using a validated instrument for people with Parkinson’s (PWP) as part of standard of care in the specialist movement disorders setting…
  • 2023 International Congress

    Effects of Boxing and conventional physiotherapy techniques in patients with PD: A randomized control study

    W. Kamel, M. Asala, A. Al-Tajalli, A. Al-Tammar, R. Alkhaldi, C. Ramos Jr, A. Mubarak (beni suef, Egypt)

    Objective: To determine the effectiveness of boxing vs. conventional physiotherapy techniques in improving the quality of movement, motor, cognitive functions in patients with PD. Background:…
  • 2023 International Congress

    Hereditary spastic paraplegia type 4 (SPG4): an international multicenter clinical and genetic study

    A. Orlacchio, E. Panza, R. Rumore, C. Montecchiani, F. Gaudiello, M. Stasi, A. Stigliano, M. Miele, R. Massa, M. Bassi, A. Tessa, F. Santorelli, A. Meyyazhagan, P. St George-Hyslop, J. Pedroso, O. Barsottini, H. Teive, R. Miyamoto, T. Kawarai (Rome, Italy)

    Objective: To describe the epidemiological, clinical, and genetic features of patients affected by hereditary spastic paraplegia (HSP) in an international cohort of affected individuals.To describe…
  • 2023 International Congress

    A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson’s disease

    M. Pimentel Piemonte, M. Dalencar, G. Venas, A. Helene, A. Roque, J. Vivas (Sao Paulo, Brazil)

    Objective: To investigate the effectiveness of a two-dimensional gait assessment to identify the decline in gait performance associated with Parkinson's disease progression Background: Gait is…
  • 2023 International Congress

    Prevalence of urinary symptoms and its impact on life quality in patients living with parkinson disease in a mexican population

    A. Herrera Ruiz, D. Aguila-Godinez, M. Ruiz-Mafud, M. Medrano-Delgado, A. Domínguez-García, E. Santiago-Delacruz, A. Regalado-Mustafá, M. Medina-Pérez, L. Lira-Juarez,, G. Hernández-Armesto, K. Talavera-Lagunas, J. García-Hernández, A. Hernández-Medrano, D. Romero-Teran, A. Alcocer-Salas, G. Cerda Hernández, A. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: To describe the prevalence and the impact on the quality of life in patients living with Parkinson’s disease with urinary symptoms. Background: Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley